Expert Interviews

Vaccine mRNA technology has revolutionized the vaccination landscape.

Bill Snyder, CEO of Vivante Health, explains how the organization's digestive health service through digital health is benefiting patients by personalizing their care and being supported in their care journey with the help of their primary care physician or gastroenterologist.

CEO of Vivante Health, Bill Snyder, shares how an integrated or "full-stack" digital health system can benefit patient care all around, amid safety concerns about digital health and the security of sensitive health information. Snyder also introduces Vivante's digestive health platform and how it's associated with the organization's digital health innovations. For example, they've invested in looking at disparate data sets and using AI and machine learning to leverage pattern recognition and recognize specific patient needs.

Implementing prescription digital therapeutics can increase effectiveness of treatment pathways.

Utilization of PDTs provides an array of financial considerations in treatment decisions.

Dr Lewis provides insight into general unmet needs surrounding vaccines.

Vaccine accessibility has been limited for patients impacted by health disparities and social determinants of health (SDoH).

Elizabeth Johnson, CEO of MedicoCX shared the importance of trust in healthcare and how it's been missing in drug development, marketing and delivery. Johnson said one way drug companies could build trust is including patients sooner so they're part of the process beyond clinical trials.

Connie Sullivan, president and CEO of the National Home Infusion Association, addressed the benefits of home-based infusion care, the types of treatments offered to patients and its reimbursement considerations. Sullivan presented on this form of care during the Asembia 2023 Specialty Pharmacy Summit in Vegas this week.

Ray Tancredi, VP of Walgreens mentioned in the last decade or so there have been many oncology drug approvals. Over time, the number of approvals decreased each year.

Today at the annual Asembia Specialty Summit in Las Vegas, Sarah Marche, VP of Pharmacy at Highmark Health, spoke alongside other professionals from various stakeholders within the industry who are invested some way in digital therapeutics.

Today at Asembia 2023 Specialty Pharmacy Summit in Las Vegas, Alexander Pham, VP of Client Services & Strategy at Clearway Health, talked about their collaboration with safety net hospital, OU Health, alongside the Chief Administrative Officer of OU Health, Jigar Thakkar. In this interview, Pham talked about how the Clearway and OU Health partnership helped build a specialty pharmacy program, alleviate financial burden, and more.

Ray Tancredi talked about the upcoming pipeline and more in this interview with Managed Healthcare Executive.

Megan Coder, PharmD, MBA, leads a discussion surrounding the evolution of software applications in the clinical setting.

Prescription digital therapeutics (PDTs) are explored in behavior-driven conditions, such as substance abuse disorders.

Dr Lewis discusses his organization’s leveraging of EMR to track immunization status of patients.

The COVID-19 pandemic has influenced patient perception regarding many aspects of vaccination safety and efficacy.

James Lewis, PharmD, FIDSA, opens a discussion regarding the current and anticipated landscape surrounding vaccination.

In this final part of a two-part video series, Clay Wilemon, CEO of 4L Data Intelligence, shared how much in cost that fraud, waste and abuse has affected healthcare due to issues like overpayment; and how leveraging your artificial intelligence can help solve fraudulent issues. Clay added how much the industry can save using these solutions.

In closing thoughts, the experts provide insight regarding the future of genetic testing in ALS treatment management.

The unmet needs in ALS treatment management are explored.

Clay Wilemon, CEO of 4L Data Intelligence addresses how fraud, waste and abuse in healthcare is an issue caused mainly by overbilling.

Medical experts discuss genetically targeted treatments for patients diagnosed with ALS.

The impact of genetic testing for ALS on a population health level.

Understanding how common genetic mutations in patients with ALS plays a role in prognosis.

Various approaches to genetic testing for ALS are explored.

Payer considerations for providing access to genetic testing are explored by key opinion leaders.

Experts discuss the driving factors behind costs within the treatment landscape of ALS.

Yoona Kim, PharmD, PhD, co-founder, CEO of Arine Inc., talked about the relationship between racial health disparities and medication non-adherence, and how artificial intelligence can help improve adherence between groups most affected such as Black, Latino and Asian populations.

Focusing on preventing diabetes and reducing disparities across populations, Dr Greene highlights ways to improve affordability and access to new treatment technologies.